This presentation discusses:
- Potential causes and published examples of unwanted immunogenicity;
- Best strategies for early immunogenicity testing and pipeline de-risking;
- Functional in vitro assays and other discovery tools to accelerate drug development.
Download Document
Related Insights
Specifica Antibody Discovery Campaigns
Specifica Library Platform Transfer
Specifica Affinity Maturation & Developability Optimization
Discovery Sciences – Innovative Antibody Drug Discovery Services
Multiplex Immunoassays for Idiopathic Pulmonary Fibrosis
Unleashing the power of MHC Associated Peptide Proteomics: Immunogenicity Assessment of Oncology Drugs
In vitro functional evaluation of immuno-oncology drug candidates in customized bioassays
Monoclonal Antibodies Reagents
